Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Public ClinicalTrials.gov record NCT05224141. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)
Study identification
- NCT ID
- NCT05224141
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 460 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab/Vibostolimab Co-Formulation Biological
- Saline placebo Drug
- Etoposide Drug
- Cisplatin Drug
- Atezolizumab Biological
- Carboplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2022
- Primary completion
- Jun 3, 2024
- Completion
- Jun 6, 2027
- Last update posted
- Jul 7, 2025
2022 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Infirmary Cancer Care ( Site 0022) | Mobile | Alabama | 36607 | — |
| Los Angeles Hematology Oncology Medical Group ( Site 0006) | Los Angeles | California | 90017 | — |
| VA West Los Angeles Medical Center ( Site 0004) | Los Angeles | California | 90073 | — |
| Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014) | Boca Raton | Florida | 33486 | — |
| Fort Wayne Medical Oncology and Hematology ( Site 0013) | Fort Wayne | Indiana | 46804 | — |
| Dana-Farber Cancer Institute ( Site 0018) | Boston | Massachusetts | 02215 | — |
| Cancer and Hematology Centers of Western Michigan ( Site 0001) | Grand Rapids | Michigan | 49503 | — |
| Hattiesburg Clinic Hematology/Oncology ( Site 0003) | Hattiesburg | Mississippi | 39401 | — |
| Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0005) | Lancaster | Pennsylvania | 17601 | — |
| Blue Ridge Cancer Care ( Site 0015) | Blacksburg | Virginia | 24060 | — |
| University of Virginia Cancer Center ( Site 0019) | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 129 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05224141, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2025 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05224141 live on ClinicalTrials.gov.